✦ LIBER ✦

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

✍ Scribed by Rummel, Mathias J; Niederle, Norbert; Maschmeyer, Georg; Banat, G Andre; von Grünhagen, Ulrich; Losem, Christoph; Kofahl-Krause, Dorothea; Heil, Gerhard; Welslau, Manfred; Balser, Christina; Kaiser, Ulrich; Weidmann, Eckhart; Dürk, Heinz; Ballo, Harald; Stauch, Martina; Roller, Fritz; Barth, Juergen; Hoelzer, Dieter; Hinke, Axel; Brugger, Wolfram

Book ID: 119941313
Publisher: The Lancet
Year: 2013
Tongue: English
Weight: 312 KB
Volume: 381
Category: Article
ISSN: 0140-6736
DOI: 10.1016/S0140-6736(12)61763-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Intensified chemotherapy with ACVBP plus

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial

✍ Christian Récher; Bertrand Coiffier; Corinne Haioun; Thierry Jo Molina; Christop 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 298 KB

Afatinib versus cisplatin plus gemcitabi

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

✍ Wu, Yi-Long; Zhou, Caicun; Hu, Cheng-Ping; Feng, Jifeng; Lu, Shun; Huang, Yuncha 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 388 KB

Erlotinib versus standard chemotherapy a

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

✍ Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massut 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 246 KB